1,660 reports of this reaction
3.7% of all PALIPERIDONE reports
#4 most reported adverse reaction
ABNORMAL WEIGHT GAIN is the #4 most commonly reported adverse reaction for PALIPERIDONE, manufactured by Janssen Pharmaceuticals, Inc.. There are 1,660 FDA adverse event reports linking PALIPERIDONE to ABNORMAL WEIGHT GAIN. This represents approximately 3.7% of all 45,344 adverse event reports for this drug.
Patients taking PALIPERIDONE who experience abnormal weight gain should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ABNORMAL WEIGHT GAIN is moderately reported among PALIPERIDONE users, representing a notable but not dominant share of adverse events.
In addition to abnormal weight gain, the following adverse reactions have been reported for PALIPERIDONE:
The following drugs have also been linked to abnormal weight gain in FDA adverse event reports:
ABNORMAL WEIGHT GAIN has been reported as an adverse event in 1,660 FDA reports for PALIPERIDONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ABNORMAL WEIGHT GAIN accounts for approximately 3.7% of all adverse event reports for PALIPERIDONE, making it a notable side effect.
If you experience abnormal weight gain while taking PALIPERIDONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.